Although clearly different from the conventional TC-NER pathway, the protection from cytotoxic transcription-blocking DPCs—impaired by the loss of either CSB or CSA—may explain the severe Cockayne syndrome features in patients of the respective gene complementation groups, contrasting with the mild phenotypes linked to known UVSSA mutations. The gene discussed is ERCC6; the disease is Cockayne syndrome.